Pancreatic ductal adenocarcinoma (PDAC) is both the most common and the deadliest type of pancreatic cancer. Most treatment ...
Pancreatic cancer is notoriously hard to treat, often resisting therapies that target its most common mutations. Researchers ...
Pathogens can create sticky situations. When microbes invade the body to cause an infection, often one of their first lines ...
The phase 3 KANDLELIT-007 trial (NCT07190248) evaluating the KRAS G12C inhibitor calderasib (MK-1084) plus subcutaneous pembrolizumab and berahyaluronidase alfa-pmph (Keytruda Qlex; SC pembrolizumab) ...
Researchers at CSH Laboratory identified an oncogenic SRSF1–AURKA–MYC circuit driving pancreatic ductal adenocarcinoma.
A study led by researchers at Moffitt Cancer Center found that normal cells surrounding a tumor, known as cancer-associated ...
ELF3 axis enables luminal progenitor transformation in BRCA1-deficient breast cancer by reducing genomic instability and promoting progenitor identity.
BBO-8520 monotherapy in patients with KRASG12C non-small cell lung cancer (NSCLC) showed a 65% objective response rate (ORR) ...
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the initiation of KANDLELIT-007, a ...
Scientists at St. Jude Children's Research Hospital have revealed previously unappreciated roles for the retrotransposon LINE-1 in shaping the cancer genome structure and regulation.
Explore how aggressive breast cancer evades immune defences and discover potential treatment strategies with our latest ...
Scientists at St. Jude Children’s Research Hospital found that tumor cells use LINE-1 retrotransposons to restructure the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback